Skip to main content

Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

The Original Article was published on 27 October 2022

Correction: Arthritis Res Ther 24, 240 (2022)

https://doi.org/10.1186/s13075-022-02934-3

Following publication of the original article [1], the authors reported an error in Additional file 1: Figure S1, Panel (C), subpanel c) a description regarding the gating strategy for the activated Th17 cells.

The data currently reads:

  • Activated Th17 cells: CD3+, CD4+, CXCR3+, CCR6+, CD38+, HLA-DR+

The data should read:

  • Activated Th17 cells: CD3+, CD4+, CXCR3-, CCR6+, CD38+, HLA-DR+

Reference

  1. Ueno M, Miyagawa I, Miyazaki Y, et al. Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis Res Ther. 2022;24:240. https://doi.org/10.1186/s13075-022-02934-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoshiya Tanaka.

Supplementary Information

Additional file 1: Figure S1.

Flow cytometry gating strategy. The proportion of A. CD4+ T cells subsets to CD3+ and CD4+ T cells (%), B. CD8+ T cells subsets to CD3+ and CD8+ T cells (%), C. a)-e) Activated CD4+ T cells to CD3+ and CD4+ T cells (%) f) Activated CD8+ T cells to CD3+ and CD8+ T cells (%), D. B cells subsets to CD3- and CD19+ B cells (%), E. Classical and non-classical monocytes to CD3-, CD19-, CD20- and CD14+ cells (%), F. Myeloid and Plasmacytoid DCs to CD3-, CD19-, CD20- CD14- and human leukocyte antigen-DR+ cells (%), G. CD16+ and CD16- NK cells to CD3-, CD19-, CD20- CD14- and CD56+ cells (%).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ueno, M., Miyagawa, I., Miyazaki, Y. et al. Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis Res Ther 25, 24 (2023). https://doi.org/10.1186/s13075-023-03005-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13075-023-03005-x